# 1 <u>Title page</u>

- 2 ODIASP: An Open User-Friendly Software for Automated SMI Determination—Application
  3 to an Inpatient Population
- 4
- 5 Katia Charrière<sup>1</sup>, Antoine Ragusa<sup>2</sup>, Béatrice Genoux<sup>1</sup>, Antoine Vilotitch<sup>3</sup>, Svetlana Artemova<sup>1</sup>,
- 6 Charlène Dumont<sup>1</sup>, Paul-Antoine Beaudoin<sup>1,6</sup>, Pierre-Ephren Madiot<sup>1</sup>, Gilbert R. Ferretti<sup>4</sup>, Ivan
- 7 Bricault<sup>4</sup>, Eric Fontaine<sup>5</sup>, Jean-Luc Bosson<sup>1,6</sup>, Alexandre Moreau-Gaudry<sup>1,6</sup>, Joris Giai<sup>1,6</sup>, Cécile
  8 Bétry<sup>7</sup>
- 9
- 10 <sup>1</sup> Univ. Grenoble Alpes, Clinical Investigation Center-Technological Innovation, INSERM
- 11 CIC1406, CHU Grenoble Alpes, Public Health department, 38000 Grenoble, France
- <sup>12</sup> <sup>2</sup> Univ. Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, TIMC, 38000
- 13 Grenoble, France
- 14 <sup>3</sup> Univ. Grenoble Alpes, Data Engineering Unit, Public Health Department, Grenoble Alpes
- 15 University Hospital, 38000 Grenoble, France.
- <sup>4</sup> Univ. Grenoble Alpes, INSERM U1209, IAB, CHU Grenoble Alpes, Service de radiologie
- 17 diagnostique et interventionnelle, 38000 Grenoble, France
- <sup>5</sup> Univ. Grenoble Alpes, INSERM U1055, LBFA, CHU Grenoble Alpes, Department of
- 19 Endocrinology, Diabetology and Nutrition, 38000 Grenoble, France
- 20 <sup>6</sup> Univ. Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, CHU Grenoble
- 21 Alpes, Public Health department, TIMC, 38000 Grenoble, France
- <sup>22</sup> <sup>7</sup> Univ. Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, CHU Grenoble
- 23 Alpes, TIMC, Department of Endocrinology, Diabetology and Nutrition, 38000 Grenoble,
- 24 France
- 25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 26 Corresponding author
- 27 Prof. Cécile Bétry, MD-PhD
- 28 Université Grenoble Alpes
- 29 CHU Grenoble Alpes (CHUGA)
- 30 Service d'Endocrinologie Diabétologie Nutrition
- 31 Boulevard de la Chantourne
- 32 38700 La Tronche, France
- 33 <u>cbetry@chu-grenoble.fr</u>
- 34 Tel: +33 4 76 76 93 49

# 35 Abstract

Background: The diagnosis of malnutrition has evolved with the GLIM recommendations, which advocate for integrating phenotypic criteria, including muscle mass measurement. The GLIM framework specifically suggests using skeletal muscle index (SMI) assessed via CT scan at the third lumbar level (L3) as a first-line approach. However, manual segmentation of muscle from CT images is often time-consuming and infrequently performed in clinical practice. This study aims to develop and validate an open-access, user-friendly software tool called ODIASP for automated SMI determination.

43 Methods: Data were retrospectively collected from a clinical data warehouse at Grenoble Alpes 44 University Hospital, including epidemiological and imaging data from CT scans. All 45 consecutive adult patients admitted in 2018 to our tertiary center who underwent at least one 46 CT scan capturing images at the L3 vertebral level and had a recorded height were included. 47 The ODIASP tool combines two algorithms to automatically perform L3 slice selection and 48 skeletal muscle segmentation, ensuring a seamless process. Agreement between cross-sectional 49 muscle area (CSMA) values obtained via ODIASP and reference methodology was evaluated 50 using the intraclass correlation coefficient (ICC). The prevalence of reduced SMI was also 51 assessed.

52 <u>Results</u>: SMI values were available for 2,503 participants, 53.3% male, with a median age of 53 66 years [51-78] and a median BMI of 24.8 kg/m<sup>2</sup> [21.7-28.7]. There was substantial agreement 54 between the reference method and ODIASP (ICC: 0.971; 95% CI: 0.825 to 0.989) in a 55 validation subset of 674 CT scans. After correcting for systematic errors (a 5.8 cm<sup>2</sup> [5.4-6.3] 56 overestimation of the CSMA), the agreement improved to 0.984 (95% CI: 0.982 to 0.986), 57 indicating excellent agreement. The prevalence of reduced SMI was estimated at 9.1% overall

- 58 (11.0% in men and 6.6% in women). To facilitate usage, the ODIASP software is encapsulated
- 59 in a user-friendly interface.

60 <u>Conclusions</u>: This study demonstrates that ODIASP is a reliable tool for automated muscle 61 segmentation at the L3 vertebra level from CT scans. The integration of validated AI algorithms 62 into a user-friendly platform enhances the ability to assess SMI in diverse patient cohorts, 63 ultimately contributing to improved patient outcomes through more accurate assessments of 64 malnutrition and sarcopenia.

# 65 Key words

- 66 Sarcopenia, Malnutrition, Image Processing, Computer-Assisted, Computational Neural
- 67 Networks, Skeletal Muscle, Body composition

# 68 Introduction

69 Since the release of the GLIM recommendations, malnutrition diagnosis has been based on both phenotypic and etiological criteria<sup>1</sup>. In current clinical practice, phenotypic criteria for 70 71 malnutrition primarily involve mainly Body Mass Index (BMI) and weight loss assessments <sup>2,3</sup>. However, a large proportion of patients are not weighed during hospitalization <sup>4</sup>. The GLIM 72 framework recommends that muscle mass assessments should be performed as a first-line 73 74 approach to detect muscle mass reduction using one of three methods: dual-energy x-ray 75 absorptiometry (DEXA), computerized tomography (CT) scan, or bioelectrical impedance 76 analysis (BIA). For CT, the cross-sectional muscle area (CSMA) at the third lumbar vertebra 77 (L3) is recommended to calculate the skeletal muscle index (SMI). However, manual segmentation of muscle from CT images is time-consuming<sup>3</sup>. 78

79 AI algorithms have the potential to automate SMI determination, potentially extending 80 the use of CT scan for malnutrition diagnosis in clinical practice and across large volumes of CT scans <sup>5</sup>. Although research in AI-driven CT scan analysis is expanding, a significant gap 81 82 persists between technological advancements and clinical integration. We hypothesize that part 83 of this gap arises from the lack of user-friendly interfaces that facilitate the application of these algorithms. Furthermore, few comprehensive solutions exist that provide a fully automated 84 85 pipeline for SMI determination, including both L3 slice identification and muscle segmentation. 86 Existing tools are often developed within specific cohorts, limiting their applicability for 87 malnutrition screening in broader, unselected patient populations  $^{6-8}$ .

88 This study is a part of a larger research project: the Optimization of the DIAgnosis of 89 SarcoPenia through the automated determination of SMI (ODIASP) study. Our primary 90 objective was to develop and validate an open-access, user-friendly software for the automated 91 determination of the Skeletal Muscle Index (SMI) in clinical research. Additionally, we aimed

5

- 92 to evaluate the potential of this tool in identifying the risk of reduced SMI within a cohort of
- 93 patients managed at a tertiary hospital.

#### 94 <u>Methods</u>

95

#### 96 Ethics statement

97 The ODIASP study was conducted in accordance with the ethical standards laid down 98 in the 1964 Declaration of Helsinki and its later amendments. Ethical approval was obtained on 99 18 August 2021 by the regional ethics committee (CECIC Rhône-Alpes-Auvergne, Clermont-100 Ferrand, IRB 5891). In compliance with current French legislation for retrospective studies 101 using clinical data, participants were individually informed that their data could be used for 102 research purposes (in line with the MR-004 CNIL reference methodology). Individuals who 103 objected to the use of their data or those with incomplete or outdated contact information were 104 excluded from the study.

105

## 106 Study participants

107 All consecutive participants aged 18 years and older, admitted to Grenoble University 108 Hospital (CHU Grenoble Alpes) between January and December 2018, who underwent at least 109 one CT scan potentially capturing images at the L3 vertebral level and who had a recorded 110 height were retrospectively included in the study. Participants with non-abdominal CT scans, 111 including spinal or thoracic CT scans, were also eligible, as these may contain images at the L3 112 level. This inclusion was particularly relevant for assessing whether the ODIASP software 113 could effectively detect CT scans that lacked an L3 slice. When multiple CT scans were 114 available for a patient during the inclusion period, the scan most likely to include the L3 slice 115 was selected for analysis. A subset of this population had been previously defined for preliminary research <sup>9</sup> and was utilized for validation. 116

117 Data collection

118 Data were retrospectively collected from the clinical data warehouse (CDW) PREDIMED 119 (French acronym for Plateforme de Recueil et d'Exploitation des Données bIoMEDicales), implemented at the Grenoble Alpes University Hospital <sup>10,11</sup>. All structured data were 120 121 pseudonymized and CT scans were de-identified. This de-identification of CT scans was carried out by: 1) removing all identifiable Digital Imaging and Communication in Medicine (DICOM) 122 123 tags following the basic profile recommendations of the DICOM standard<sup>1</sup>, and 2) excluding 124 all derived images (i.e., images where pixel values are derived or computed from other images, 125 such as screenshots or dose reports) based on the 'ImageType' DICOM attribute. 126 The following data were collected 127 General data: age, sex, height, weight \_ Imaging data: CT scans, including abdominal area, in DICOM format with 128 \_ metadata. Since contrast enhancement does not influence cross-sectional skeletal 129 130 muscle area, both CT images with and without contrast administration were eligible <sup>12,13</sup>. CT images could originate from different CT machines (Optima CT660 GE 131 132 Healthcare, Revolution CT GE Healthcare, Siemens Somatom Definition Edge, 133 Revolution HD GE Healthcare, Revolution EVO GE Healthcare, Toshiba Aquilion 134 and Siemens Somatom Definition AS+). 135

## 136 Cross sectional muscle area (CSMA) determination

137 Reference Method


All processing was performed on a single GPU machine (NVIDIA TITAN RTX 16 graphics card, a 3.7 GHz CPU, and 64 GB of RAM) with an Intel(R) Xeon(R) W-2135 processor. The third lumbar (L3) vertebra was manually identified by a medical expert on the sagittal reconstruction using the Picture Archiving and Communication System (PACS) in

<sup>&</sup>lt;sup>1</sup> https://dicom.nema.org/medical/dicom/current/output/html/part15.html#sect\_E.1.1

142 DICOM format. For each participant, a slice approximately halfway along the vertebra was 143 selected for muscle segmentation, with the identification of slices at both the lower and upper 144 extremities. Skeletal muscle was then manually segmented with SliceOmatic Version 5.0 145 (Tomovision, Canada) according to previously published methods to obtain the CSMA<sup>9</sup>. The 146 abdominal muscles (transversus abdominis, external and internal obliques and rectus 147 abdominis), the paraspinal muscles (erector spinae and quadratus lumborum) and the psoas 148 muscle were segmented using Hounsfield unit (HU) values ranging from -29 to 150<sup>14</sup>.

149 ODIASP tool

150 The ODIASP tool integrates two open-source algorithms: 1) for the automatic selection 151 of a slice at the level of the L3 vertebra, and 2) for the automatic segmentation of skeletal muscle 152 in this slice (Figure 1). For the first step, we employed the L3 slice selection algorithm developed by Bridge et al.<sup>15</sup> This algorithm, based on a DenseNet Convolutional Neural 153 154 Network (CNN), was trained and validated using ODIASP project data through 5-fold cross-155 validation. A batch size of 64 images, a learning rate of 0.001, and a dropout rate of 0 were 156 selected, while other hyperparameters proposed by Bridge et al. were maintained during the 157 training phase. For the second step, we utilized the AutoMATiCA algorithm developed by Paris et al. <sup>16</sup>. The proposed U-Net model for automated segmentation of skeletal muscle was 158 previously validated on ODIASP project CT data 9. 159





161 Figure 1. Schematic overview of the architecture of the ODIASP tool


The ODIASP tool is based on two previously published algorithms from Bridge et al. <sup>15</sup> and
Paris et al. <sup>16</sup>.

164 Statistical analysis

165 Characteristics of the cohort were presented as medians with interquartile ranges (IQR) 166 or using frequencies and proportions depending on their nature. The agreement between the 167 CSMA values calculated by ODIASP and those obtained using the reference methodology was 168 assessed using the intraclass correlation coefficient (ICC) along with 95% confidence intervals. 169 This analysis was complemented with a mixed regression model. The interpretation of the 170 strength of agreement between the two methods was based on the criteria established by Koo 171 and Li: an ICC value < 0.5 indicated poor reliability, a value between 0.5 and 0.75 indicated 172 moderate reliability, a value between 0.75 and 0.90 indicated substantial reliability, and a value > 0.90 indicated excellent reliability <sup>17</sup>. For determining the reduction in SMI within our sample, 173 thresholds were derived from the study by van der Werf et al <sup>18</sup> and are applicable only to the 174 175 subpopulation aged 20 to 79 years with a BMI ranging from 17 to 35 kg/m<sup>2</sup>. and were applicable 176 only to the subsample of participants aged 20 to 79 years with a BMI ranging from 17 to 35 177 kg/m<sup>2</sup>. Statistical analyses were conducted using Stata (version 15) with p-values <0.05 178 considered statistically significant and without adjustment for test multiplicity.

# 179 **Results**

- 180 Participant inclusion and characteristics
- 181 A total of 3300 participants were included and 2503 participants were analyzed (Figure
- 182 2). Their median age was 66 [51–78] years with 1334 (53.3%) males. The median BMI was
- 183 24.8 [21.7–28.7] kg/m<sup>2</sup>, with 174 (7.3%) having a BMI < 18.5 kg/m<sup>2</sup> and 459 (19.3%) classified
- as obese. The median SMI was 45.1 [38.4–52.5] cm<sup>2</sup>/m<sup>2</sup>. Participants were hospitalized in the
- 185 following units: day hospital (11.0%), medicine (27.4%), geriatrics (2.8%), surgery (10.4%),
- 186 intensive care (6.1%), rehabilitation (1.8%), and emergency care (40.5%).




187

## 188 Validation of the ODIASP tool

189 The ODIASP tool operates through two main steps: first, identifying a L3 slice and 190 second, segmenting the skeletal muscle (Figure 1). For the first step, we validated the algorithm

191 from Bridge et al. The algorithm correctly identified the L3 slice in 88% of cases (95% CI: 192 85.49 to 90.50, n=596). For slices outside the L3 level (n=80), the median distance from the 193 chosen L3 slice was -5.6 mm [-17.5 to 12.5], indicating that the slices were, on average, 5.6 194 mm below the lower extremity of the L3 vertebra. The algorithm for the second step, muscle 195 segmentation, was previously validated externally <sup>9</sup>. 196 To validate the entire pipeline, we compared the cross-sectional muscle area (CSMA) 197 obtained using the reference method with that generated by the ODIASP tool in the validation 198 subset. ODIASP failed to provide results for two participants (Figure 2). There was substantial 199 agreement between the reference method and ODIASP (ICC: 0.971; 95% CI: 0.825 to 0.989) 200 (Figure 3). After correcting for systematic errors (a 5.8 cm<sup>2</sup> [5.4-6.3] overestimation of the 201 CSMA), there was excellent agreement (ICC:0.984, 95% CI: 0.982 to 0.986).

202



203


Figure 3. Scatterplot comparing cross-sectional muscle area (CSMA) measurements obtained with the reference method and the ODIASP tool (n = 674).

Each data point represents an individual measurement, and the dashed line signifies perfect agreement between the two methods. The proximity of data points to the dashed line indicates a high degree of agreement.

209

# 210 An Open-Access and User-Friendly Interface

To facilitate the use of the ODIASP tool, we encapsulated the code into a user-friendly software interface (Figure 4A). The interface displays the sagittal view with the chosen L3 slice localization, the L3 slice itself, and its segmentation, allowing for easy visual validation of results (Figure 4B). This software is freely available at https://odiasp.timc.fr/ (Figure 4C).



- 215
- 216 Figure 4. The ODIASP tool: an open access software with user-friendly interface
- 217 (A) User interface
- 218 (B) Example of muscle segmentation
- 219 (C) QR code for downloading the ODIASP Software

220 ODIASP allows processing of large sets of CT scans without the need for pre-treatment.

221 It takes approximately 4 minutes to analyze one CT scan. In some cases, ODIASP did not

222 correctly identify or segment muscle. However, the interface allows for quick visual inspection

- 223 of the results if necessary.
- 224 Risk of reduced SMI in a large cohort of hospitalized participants
- 225 Based on previously published cut-off values for individuals aged 20-79 years with a
- BMI between 17 and 35 kg/m<sup>2</sup>, 103 of 937 men (11.0%) and 46 of 699 women (6.6%) were 226
- 227 considered to have reduced skeletal muscle mass, representing a total of 9.1% of the participants
- with an available cut-off<sup>18</sup>. 228

14

#### 229 Discussion

This study aimed to develop and validate a tool for the automated determination of SMI at the L3 vertebra level using CT scan in a large population. We integrated AI algorithms into a user-friendly software, making advanced technologies accessible to clinical researchers who may be unfamiliar with them.

#### 234 <u>Reliability of the ODIASP automated tool</u>

Most previous studies have focused on tissue segmentation at the L3 level <sup>16,19,20</sup>, with 235 236 few addressing the challenge of developing a fully automated pipeline for L3 SMI determination. To our knowledge, we are the first to develop and validate automated AI 237 238 software for L3 SMI determination in an unselected population of patients managed at a tertiary hospital across various units, including emergency and intensive care. Previous tools have been 239 developed for specific populations, such as cancer patients <sup>6,7</sup> or mixed cohorts including 240 241 cancer, sepsis, and healthy subjects<sup>8</sup>. Our approach involved utilizing previously published 242 algorithms and validating them in our cohort, demonstrating good reliability across a large 243 sample. We achieved accurate identification of most L3 slices, with 88% correctly positioned 244 at the L3 vertebra, which aligns with previous findings (Delrieu et al.: 91.2% and 74.1% in, two datasets<sup>6</sup>). Slices identified outside of the L3 level showed a median deviation of -5.6 mm [-245 246 17.5; 12.5], typically locating them at adjacent vertebrae, given the approximate height of vertebrae (30 mm) and intervertebral disks (10 mm)<sup>21</sup>. A prior study indicates that CSMA at 247 neighboring vertebrae are relatively comparable <sup>22</sup>. The reliability of muscle segmentation was 248 previously validated <sup>9</sup>, and our full pipeline demonstrated substantial to excellent reliability. 249

250 <u>Clinical implications</u>

The prevalence of reduced SMI has mainly been studied in cancer populations  $^{23-25}$ . To our knowledge, our study is the first to assess it in a large cohort of unselected patients, with the sole inclusion criteria being the availability of a CT scan. The cut-offs for defining reduced

SMI remains controversial, while the cut-offs proposed by Prado et al. <sup>14</sup> have been widely used, they are specific to patients with obesity and cancer and can lead to an overestimation of reduced SMI prevalence <sup>26</sup>. In our study, we referred to the cut-offs by Van der Werf et al.<sup>18</sup>, which are applicable to a Caucasian population and align well with our predominantly Caucasian cohort. Furthermore, Van der Werf et al. provide age- and BMI-specific cut-offs, enhancing the relevance of our findings. Our research indicates that 9% of the patients in our tertiary hospital setting have reduced muscle mass.

## 261 Study limitations

262 Several limitations should be acknowledged. First, we trained the algorithm of Bridge 263 et al. on our dataset since it was only available in an untrained version. Consequently, our tool 264 lacks full external validation. Second, when testing ODIASP on the analyzed populations, we 265 identified some processing failures. Human oversight remains essential for maintaining data 266 quality; thus, our software provides features for visual manual validation, in line with the recent European Union AI Act emphasizes the necessity of human oversight in algorithmic decision-267 268 making <sup>27</sup>. Third, processing large datasets can be time-consuming; for instance, analyzing 269 1,000 scans requires just over 24 hours with a standard desktop computer. However, the process 270 is fully automated and runs in the background. Our approach involved testing ODIASP under 271 real-life conditions, using scans with multiple series, including those that did not contain the L3 272 vertebra, which lengthened the process but reduced the time necessary to preprocess the data. Additionally, it is important to acknowledge that some CT scans may have insufficient quality 273 274 for accurate segmentation, a factor that should be considered in future clinical research. Lastly, 275 ODIASP tends to slightly overestimate the CSMA compared to the ground truth. This 276 discrepancy reflects a systematic error comparable to inter-expert variability and could be partly 277 influenced by the overestimation observed with AutoMATiCA or the fact that the ground truth was constructed at our center by only two experts  $^{9,16}$ . 278

#### 279 Futures directions

280 Future work will focus on enhancing the reliability of our software. A strength of this 281 project is our access to diverse medical imaging data through the CDW PREDIMED, allowing 282 for the inclusion of patients from various units and with different pathologies. However, our study is monocentric, which may lead to overfitting and limit generalizability. Traditional 283 284 training methods can overestimate model accuracy by about 20% due to hidden Data Acquisition Bias-Induced Shortcuts (DABIS)<sup>28</sup>. Strategies to increase reliability include using 285 286 external training datasets and applying appropriate data preparation and partitioning techniques (training, validation, and testing sets) to improve generalizability <sup>29–31</sup>. Additionally, methods 287 to address biases without external datasets can also be applied <sup>28</sup>. Our objective is to develop 288 extensive cohorts for studying malnutrition and sarcopenia in inpatients. However, many 289 290 patients do not undergo abdominal CT scans. To address this limitation, we plan to enhance 291 ODIASP's capabilities to analyze chest CT scans, considering the growing interest in assessing SMI at the T12 vertebra level <sup>32</sup>. We also plan to validate the segmentation of other tissues— 292 293 intermuscular, visceral, and subcutaneous adipose tissue-performed in AutoMATiCA before 294 integrating it into ODIASP<sup>16</sup>. It is important to note that ODIASP is not yet CE marked or FDA 295 approved, limiting its use to clinical research rather than routine practice. Our ultimate goal is 296 to deploy this software in clinical settings after obtaining all mandatory regulatory 297 authorization.

298

# 299 Conclusion

The results of this study demonstrate that ODIASP is a reliable tool for the automated segmentation of muscles at the L3 vertebra level from CT scans. Integrating validated AI algorithms into a user-friendly software platform can significantly enhance clinical researchers' ability to assess SMI in large, diverse patient cohorts. We anticipate that our research will

- 304 facilitate a deeper understanding of the impact of reduced SMI, ultimately contributing to
- 305 improve patient outcomes through more accurate malnutrition and sarcopenia assessments.

## 306 Funding

This work was supported by a grant from the Regional Delegation for Clinical Research of the University Hospital Grenoble Alpes in 2019 and MIAI@Grenoble Alpes, (ANR-19-P3IA-0003). The funding bodies did not have any involvement in the design/conduct of the research, in data analysis/interpretation, or in writing/approval of the manuscript.

311

#### 312 Conflict of interest Statement

Katia Charrière, Antoine Ragusa, Béatrice Genoux, Antoine Vilotitch, Svetlana
Artemova, Charlène Dumont, Paul-Antoine Beaudoin, Pierre-Ephren Madiot, Gilbert R.
Ferretti, Ivan Bricault, Jean-Luc Bosson, Eric Fontaine, Alexandre Moreau-Gaudry, Joris Giai
and Cécile Bétryhave no relevant conflict of interest to disclose.

317

## 318 Ethical guidelines statement

The ODIASP study was conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Ethical approval was obtained on 18 August 2021 by the regional ethics committee (CECIC Rhône-Alpes-Auvergne, Clermont-Ferrand, IRB 5891). In compliance with current French legislation for retrospective studies using clinical data, participants were individually informed that their data could be used for research purposes (in line with the MR-004 CNIL reference methodology)

#### 325 References

- 326 1. Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi 327 T et al. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global 328 clinical nutrition community. Clin Nutr 2019;38:1-9.
- 329 Ulmann G, Cherbuy C, Guerriero E, Jirka A, Le Gall M, Neuzillet C et al. 2.
- 330 Modifications des recommandations de la Haute Autorité de santé concernant le diagnostic de
- 331 la dénutrition : application par les professionnels de la nutrition en pratique clinique. Nutrition
- 332 Clinique et Métabolisme 2023;37:168-175.
- 333 Barazzoni R, Jensen GL, Correia MITD, Gonzalez MC, Higashiguchi T, Shi HP et al. 3.
- 334 Guidance for assessment of the muscle mass phenotypic criterion for the Global Leadership
- 335 Initiative on Malnutrition (GLIM) diagnosis of malnutrition. Clinical Nutrition
- 336 2022;41:1425-1433.
- 337 Lambert K, Ferguson A, Meletis M, Charlton K. How frequently are patients weighed 4. 338 in hospital? Results from a five-year cross-sectional audit of clinical practice in nine
- 339 hospitals. Clinical Nutrition ESPEN 2020;36:157-161.
- 340 Rozynek M, Kucybała I, Urbanik A, Wojciechowski W. Use of artificial intelligence 5. 341 in the imaging of sarcopenia: A narrative review of current status and perspectives. Nutrition 342 2021;89:111227.
- 343 Delrieu L, Blanc D, Bouhamama A, Reyal F, Pilleul F, Racine V et al. Automatic 6. 344 deep learning method for third lumbar selection and body composition evaluation on CT 345 scans of cancer patients. Front Nucl Med 2024:3.
- 346 Islam S, Kanavati F, Arain Z, Costa OFD, Crum W, Aboagye EO et al. Fully 7.
- automated deep-learning section-based muscle segmentation from CT images for sarcopenia 347 348 assessment. Clinical Radiology 2022;77:e363-e371.
- 349 Ha J, Park T, Kim H-K, Shin Y, Ko Y, Kim DW et al. Development of a fully 8. 350 automatic deep learning system for L3 selection and body composition assessment on 351 computed tomography. Sci Rep 2021;11:21656.
- 352 Charrière K, Boulouard Q, Artemova S, Vilotitch A, Ferretti GR, Bosson J-L et al. A 9. 353 comparative study of two automated solutions for cross-sectional skeletal muscle
- 354 measurement from abdominal computed tomography images. Medical Physics 2023;50:4973-355 4980.
- 356 10. Artemova S, Madiot P-E, Caporossi A, Group P, Mossuz P, Moreau-Gaudry A.
- 357 PREDIMED: Clinical Data Warehouse of Grenoble Alpes University Hospital. *MEDINFO*
- 358 2019: Health and Wellbeing e-Networks for All 2019;1421–1422.
- 359 Charrière K, Madiot P-E, Artemova S, Tep P, Lenne C, Cohard B et al. ODIASP: 11.
- Clinically Contextualized Image Analysis Using the PREDIMED Clinical Data Warehouse, 360 Towards a Better Diagnosis of Sarcopenia. Stud Health Technol Inform 2022;290:1068-1069. 361
- Paris MT, Furberg HF, Petruzella S, Akin O, Hötker AM, Mourtzakis M. Influence of 362 12.
- 363 Contrast Administration on Computed Tomography-Based Analysis of Visceral Adipose and
- 364 Skeletal Muscle Tissue in Clear Cell Renal Cell Carcinoma. JPEN J Parenter Enteral Nutr
- 365 2018 doi:10.1002/jpen.1067.
- van Vugt JLA, Coebergh van den Braak RRJ, Schippers HJW, Veen KM, Levolger S, 366 13.
- 367 de Bruin RWF et al. Contrast-enhancement influences skeletal muscle density, but not
- 368 skeletal muscle mass, measurements on computed tomography. Clin Nutr 2017
- 369 doi:10.1016/j.clnu.2017.07.007.
- 370 Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L et al. 14.
- 371 Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of
- 372 the respiratory and gastrointestinal tracts: a population-based study. The Lancet Oncology
- 373 2008;**9**:629–635.

- 374 15. Bridge CP, Rosenthal M, Wright B, Kotecha G, Fintelmann F, Troschel F et al. Fully-Automated Analysis of Body Composition from CT in Cancer Patients Using Convolutional 375 376 Neural Networks. 2018. pp. 204–213.
- 377 Paris MT, Tandon P, Heyland DK, Furberg H, Premji T, Low G et al. Automated 16.
- 378 body composition analysis of clinically acquired computed tomography scans using neural 379 networks. Clinical Nutrition 2020;39:3049-3055.
- 380 Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation 17.
- 381 Coefficients for Reliability Research. J Chiropr Med 2016;15:155–163.
- van der Werf A, Langius JAE, de van der Schueren MAE, Nurmohamed SA, van der 382 18.
- 383 Pant KAMI, Blauwhoff-Buskermolen S et al. Percentiles for skeletal muscle index, area and
- 384 radiation attenuation based on computed tomography imaging in a healthy Caucasian 385 population. Eur J Clin Nutr 2018:72:288–296.
- 386 19. Shen H, He P, Ren Y, Huang Z, Li S, Wang G et al. A deep learning model based on 387 the attention mechanism for automatic segmentation of abdominal muscle and fat for body 388 composition assessment. *Quant Imaging Med Surg* 2023;13:1384–1398.
- 389 20. Pu L, Gezer NS, Ashraf SF, Ocak I, Dresser DE, Dhupar R. Automated segmentation 390 of five different body tissues on computed tomography using deep learning. Med Phys
- 391 2023;50:178-191.
- 392 21. Zhou SH, McCarthy ID, McGregor AH, Coombs RRH, Hughes SPF. Geometrical
- 393 dimensions of the lower lumbar vertebrae – analysis of data from digitised CT images. Eur 394 *Spine J* 2000;**9**:242–248.
- 395 22. Park J, Gil JR, Shin Y, Won SE, Huh J, You M-W et al. Reliable and robust method 396 for abdominal muscle mass quantification using CT/MRI: An explorative study in healthy 397 subjects. PLoS One 2019;14:e0222042.
- 398 23. Raoul P, Cintoni M, Coppola A, Alfieri S, Tortora G, Gasbarrini A et al. Preoperative
- 399 low skeletal muscle mass index assessed using L3-CT as a prognostic marker of clinical
- 400 outcomes in pancreatic cancer patients undergoing surgery: A systematic review and meta-401 analysis. Int J Surg 2023 doi:10.1097/JS9.000000000000989.
- 402 24. de Luis Roman D, López Gómez JJ, Muñoz M, Primo D, Izaola O, Sánchez I.
- 403 Evaluation of Muscle Mass and Malnutrition in Patients with Colorectal Cancer Using the
- 404 Global Leadership Initiative on Malnutrition Criteria and Comparing Bioelectrical Impedance 405 Analysis and Computed Tomography Measurements. Nutrients 2024;16:3035.
- 406 25. Anabtawi NM, Pasala MS, Grimshaw AA, Kharel P, Bal S, Godby K et al. Low
- 407 skeletal muscle mass and treatment outcomes among adults with haematologic malignancies:
- 408 A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2024;15:1084–1093.
- 409 26. Caudron L, Bussy A, Artemova S, Charrière K, Lakkiss SE, Moreau-Gaudry A et al.
- 410 Sarcopenia diagnosis: comparison of automated with manual computed tomography
- 411 segmentation in clinical routine. JCSM Rapid Communications 2021:4:103–110.
- 412 European Parliament. EU AI Act: first regulation on artificial intelligence. Topics 27. 413 European Parliament.
- 2024https://www.europarl.europa.eu/topics/en/article/20230601STO93804/eu-ai-act-first-414 415 regulation-on-artificial-intelligence. Accessed 25 July 2024.
- 416 Ong Ly C, Unnikrishnan B, Tadic T, Patel T, Duhamel J, Kandel S et al. Shortcut 28.
- 417 learning in medical AI hinders generalization: method for estimating AI model generalization
- 418 without external data. NPJ Digit Med 2024;7:124.
- 419 Xie C, Du R, Ho JW, Pang HH, Chiu KW, Lee EY et al. Effect of machine learning 29.
- 420 re-sampling techniques for imbalanced datasets in 18F-FDG PET-based radiomics model on
- 421 prognostication performance in cohorts of head and neck cancer patients. Eur J Nucl Med Mol
- 422 Imaging 2020;47:2826–2835.
- 423 Bradshaw TJ, Huemann Z, Hu J, Rahmim A. A Guide to Cross-Validation for 30.

- 424 Artificial Intelligence in Medical Imaging. Radiol Artif Intell 2023;5:e220232.
- 425 Willemink MJ, Koszek WA, Hardell C, Wu J, Fleischmann D, Harvey H et al. 31.
- 426 Preparing Medical Imaging Data for Machine Learning. Radiology 2020;295:4-15.
- 427 32. Molwitz I, Ozga AK, Gerdes L, Ungerer A, Köhler D, Ristow I et al. Prediction of
- 428 abdominal CT body composition parameters by thoracic measurements as a new approach to
- 429 detect sarcopenia in a COVID-19 cohort. Sci Rep 2022;12:6443.

430